echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > AI-assisted development of "old drug new use" approved by FDA

    AI-assisted development of "old drug new use" approved by FDA

    • Last Update: 2022-04-17
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    BioXcel Therapeutics announced today that the U.


    Up to 25% of people with schizophrenia and bipolar disorder experience agitation, which can range from 10 to 17 episodes per year, placing a heavy burden on patients, caregivers, and the healthcare system


    Igalmi is a sublingual film formulation of the selective alpha2 adrenergic agonist dexmedetomidine, which is rapidly acting upon oral absorption


    FDA approval is based on the results of two pivotal, randomized, double-blind, placebo-controlled Phase 3 clinical trials


    ▲Igalmi's Phase 3 clinical trial results (Image source: BioXcel's official website)

    "Igalmi is the first new acute therapy in nearly 10 years to treat agitation associated with schizophrenia or bipolar I/II disorder and represents a differentiated model for helping patients manage this symptom


    References:

    [1] BioXcel Therapeutics Announces FDA Approval of IGALMI™ (dexmedetomidine) Sublingual Film for Acute Treatment of Agitation Associated with Schizophrenia or Bipolar I or II Disorder in Adults.


    [2] A Win for AI: FDA Approves BioXCel Therapy for Bipolar Disorder and Schizophrenia.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.